Abstract
Clear cell renal cell carcinoma (ccRCC or KIRC) has a high mortality rate globally. It is necessary to identify biomarkers and investigate the mechanisms those biomarkers are associated with, to improve the prognosis of patients with KIRC. N6-Methyladenosine (m6A) affects the fate of modified RNA molecules and is involved in tumor progression. Different webservers were used in our research to investigate the mRNA transcription and clinical significance of YTHDF2 in KIRC. Survival analysis revealed that patients with elevated YTHDF2 transcription had a slightly longer OS and DFS than those with low YTHDF2 expression. YTHDF2 expression was shown to be significantly associated with the abundance of immune cells such as B cells, CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and dendritic cells. For a series of enrichment studies, we combined information on YTHDF2-binding molecules and expression-linked genes and identified the possible influence of “mRNA surveillance pathway,” “RNA degradation,” and “RNA transport” in the biology or pathogeny of KIRC. In addition, we identified multiple miRNA, kinase, and transcription factor targets of YTHDF2 in KIRC and constructed target networks. Overall, our findings show that YTHDF2 is a possible indicator of immune infiltration in the KIRC.
Highlights
kidney renal clear cell carcinoma (KIRC) is the third most common urinary system tumor, but it has the highest mortality rate (McDougal et al, 2015)
The results showed that the elevated expression of YTHDF2 was positively correlated with disease-free survival (DFS) and overall survival (OS), indicating that the KIRC patients with low expression of YTHDF2 were correlated with a poor prognosis (n 516, p < 0.05, Figure 3)
We examined whether the expression of YTHDF2 was associated with TIMER levels during immune infiltration in KIRC
Summary
KIRC is the third most common urinary system tumor, but it has the highest mortality rate (McDougal et al, 2015). It affects renal parenchymal cells and displays complex behaviors (Linehan et al, 2019). Immune therapy has revolutionized the treatment of cancer, and tumor immunology vigor (Riley et al, 2019). Immunotherapy has shown promising clinical effects in the treatment of renal cancer and has been a hot subject in the field (Xu et al, 2020). To increase the response rate, reliable tumor immunotherapy biomarkers as targets or diagnosis and evaluation indicators will be beneficial. Investigations into identifying biomarkers of KIRC and developing therapeutic agents which influence their behavior, and results in earlier
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
